Vanda Pharmaceuticals announced the start of the Thetis study, a multicenter, randomized, double‑blind, placebo‑controlled Phase III trial that will evaluate tradipitant (NEREUS) for preventing vomiting in patients receiving glucagon‑like peptide‑1 (GLP‑1) receptor agonist therapies. The trial will enroll patients who are already on a high dose of a GLP‑1 agonist and will measure the proportion of participants who remain free of vomiting during the treatment period.
The Thetis study follows a successful Phase II trial that met its primary endpoint, showing a 50 % relative reduction in vomiting episodes compared with placebo (29.3 % versus 58.6 %, p = 0.0016). Tradipitant is a selective, high‑affinity antagonist of the human substance P/neurokinin‑1 (NK‑1) receptor, blocking the neurotransmitter that triggers the vomiting reflex. By targeting this pathway, the drug offers a novel mechanism distinct from existing anti‑emetics used in oncology and motion sickness.
If the Phase III results confirm the Phase II findings, Vanda could broaden NEREUS’s indication beyond its recent FDA approval for motion sickness. The GLP‑1 receptor agonist market—driven by drugs such as semaglutide and tirzepatide—was valued at roughly $66 billion in 2025 and is projected to reach $185 billion by 2033. A successful indication for GLP‑1‑induced nausea would tap into a multi‑billion‑dollar patient population that frequently discontinues or reduces doses of these therapies due to gastrointestinal side effects.
Vanda’s management highlighted the strategic importance of this expansion. Dr. Mihael H. Polymeropoulos, President, CEO, and Chairman, noted, “Nereus marks an important advance because it introduces a completely new mechanism of action, grounded in current scientific understanding of the brain pathways that trigger vomiting.” The company’s recent financials show a $216 million revenue increase in 2025, driven by growth in its core product Fanapt®, while net losses widened to $220 million largely due to a one‑time tax charge. The Thetis trial represents a key investment aimed at generating new revenue streams and improving the company’s long‑term profitability outlook.
The announcement was well received by market participants, reflecting confidence in Vanda’s pipeline and the potential upside of tradipitant in a rapidly expanding therapeutic area. Analysts have reiterated a positive view of the company’s growth prospects, citing the trial’s potential to unlock a substantial new market and strengthen Vanda’s competitive position in the anti‑emetic space.
The trial’s initiation marks a significant milestone in Vanda’s strategy to diversify its product portfolio and capitalize on unmet medical needs in the obesity and diabetes markets. Successful outcomes could accelerate the company’s transition from a niche anti‑emetic player to a broader therapeutic innovator, potentially reshaping its revenue trajectory and investor expectations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.